Clinical trials: Allergic Rhinitis With Asthma
Type I-Allergy
Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens
Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)
- Trial name
- NCT00666341
- Testing
- rPhleum
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Allergopharma GmbH & Co. KG
Perennial Allergic Rhinitis, Asthma
Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.
Investigator examines the past prescription patterns and the reasons for the change of prescription to Monterizine capsules for Perennial Allergic Rhinitis patients with Asthma who will be taking Monterizine capsules to treat…
- Trial name
- NCT04654702
- Where
- South Korea
- Volunteers
- 2,671 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Rhinitis, Allergic, Seasonal
Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
The purpose of this study is to assess the efficacy and safety of short ragweed pollen allergen extract (MK-3641, SCH 039641, RAGWITEK™) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced…
- Trial name
- NCT02478398
- Testing
- Short ragweed pollen allergen extract, Self-injectable epinephrine, Albuterol/Salbutamol
- Volunteers
- 1,025 people
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
House Dust Mite Allergy, House Dust Mite Rhinitis
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
Rationale: Allergic rhinitis/rhinoconjunctivitis (ARC) is a global health problem, affecting 10-25% of the population. Allergen-specific immunotherapy is the only disease-modifying therapeutic option for subjects with house dust…
- Trial name
- NCT06920771
- Testing
- PURETHAL Mites 50,000 AUeq/ml
- Where
- 68 sites in Bulgaria, Germany and 3 more
- Volunteers
- 691 people
- Sponsor
- HAL Allergy
Mild Asthma and Allergic Rhinitis
To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies
The purpose of this study is to examine the safety and effects on the immune system of treatment with GSK2245035 in subjects who suffer from nasal symptoms caused by an allergy to pollen or perennial allergen, with or without…
- Trial name
- NCT01788813
- Testing
- GSK2245035
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus
Mite Asthma Pediatric Immunotherapy Trial
The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma…
- Conditions
- Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MAPIT (NCT03654976)
- Testing
- HDM SLIT-tablet
- Where
- 64 sites in United States, Bulgaria and 7 more
- Volunteers
- 533 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis Due to Grass Pollens
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
This trial is an exploratory randomised, parallel-group, double-blind, placebo- controlled, national, single-centre trial. The trial will be initiated before 2013 grass pollen season and subjects will be randomised in September…
- Trial name
- NCT01854736
- Testing
- Grazax
- Where
- 2 sites in Spain
- Volunteers
- 51 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinoconjunctivitis, Allergic Rhinitis
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
A research study of house dust mite (HDM) SLIT-tablet for the treatment of HDM allergy in Chinese participants aged 12-65.
- Trial name
- NCT07060885
- Testing
- HDM SLIT-tablet (12 SQ-HDM)
- Where
- 30 sites in China
- Volunteers
- 327 people
- Sponsor
- ALK-Abelló A/S
Asthma, House Dust Mite Allergy
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01608243
- Testing
- SLIT tablets of house dust mite allergen extracts
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Stallergenes Greer
Mite Allergy, Dermatophagoides Farinae Allergy
Retrospective Study Evaluating the Effectiveness and Safety of Immunotherapy With Clustoid Max Forte
House dust mites are the main source of allergies in indoor environments. They are predominant in coastal areas, with the Canary Islands being the autonomous community with the highest percentage of patients with…
- Conditions
- Mite Allergy, Dermatophagoides Farinae Allergy, Dermatophagoides Pteronyssinus Allergy, Rhinitis, Allergic
- Trial name
- NCT07427576
- Testing
- Clustoid® Max Forte
- Where
- 2 sites in Spain
- Volunteers
- 140 people
- Sponsor
- Inmunotek S.L.
Asthma With Allergic Rhinitis
Efficacy and Safety of HCP1102 Capsule
Efficacy and safety of HCP1102 capsule : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial.
- Trial name
- NCT02552667
- Where
- South Korea
- Volunteers
- 228 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Rhinitis; Allergic, With Asthma, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00783198
- Testing
- SCH 39641 6 Amb a 1-U, SCH 39641 12 Amb a 1-U
- Volunteers
- 565 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen
Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for IgE mediated sensitization to grass pollen 4 concentrations of a modified pollen extract of Phleum pratense are applied to find out the optimum dose.
- Conditions
- Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen, Dose-Finding Study
- Trial name
- NCT01634958
- Testing
- Depigoid Phleum
- Where
- 2 sites in Germany
- Volunteers
- 308 people
- Sponsor
- Leti Pharma GmbH
Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy
- Trial name
- NCT04874714
- Testing
- MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000)
- Where
- 13 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Inmunotek S.L.
Asthma
Singulair(R) In Asthma And Allergic Rhinitis (0476-383)
Effectiveness of adding montelukast to inhaled corticosteroids in adult subjects with both uncontrolled asthma and allergic rhinitis.
- Trial name
- NCT00545844
- Testing
- montelukast sodium
- Volunteers
- 313 people
- Sponsor
- Organon and Co
Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae, Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus, Allergic Asthma Due to Dermatophagoides Farinae
- Trial name
- NOVUS-UP (NCT07096440)
- Volunteers
- 105 people
- Sponsor
- Allergopharma GmbH & Co. KG
Allergic Rhinoconjunctivitis
Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch
This study will assess efficacy and safety of intraseasonal specific short-term immunotherapy with Depiquick® Birch in patients with allergic rhinitis and or rhinoconjunctivitis with or without intermittent asthma that have a…
- Trial name
- INSIDE (NCT01902992)
- Testing
- Depiquick Birch (DPG103)
- Where
- 35 sites in Germany
- Volunteers
- 202 people
- Sponsor
- Novartis
Asthma
Study Of Allergic Rhinitis In Patients Who Also Have Asthma
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests.
- Trial name
- NCT00296491
- Testing
- fluticasone propionate/salmeterol (FSC), montelukast (MON), fluticasone propionate (FP)
- Where
- 121 sites in United States, Canada and 2 more
- Volunteers
- 725 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis, Rhinoconjunctivitis
Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma
Safety study of Depigoid vaccine Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), to treat allergic rhinitis or rhinoconjunctivitis with or without asthma.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Mild Persistent Asthma, Mild Intermittent Asthma
- Trial name
- NCT01591343
- Testing
- Depigoid® (500 DPP/ml)
- Where
- 10 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Laboratorios Leti, S.L.